Arthrosurface’s HemiCAP system comes in the U.S., European countries, Australasia, Latin America and South Africa for various knee, shoulder, hip and great toe applications. The HemiCAP device replaces damaged cartilage surfaces with contoured implants that are matched to the individuals’ anatomy utilizing a patented, intra-operative, three dimensional mapping technology. Now in its third calendar year of commercialization, the ongoing company provides experienced strong surgeon adoption and significant annual revenue growth. Arthrosurface recently concluded its Series E funding of $5 million to provide extra working capital and additional fund its new product launches and marketing initiatives.Errol De Souza, CEO and President of Biodel. These money will be centered on applying our proprietary technology for the advancement of ultra-rapid-performing insulin formulations for the treating insulin resistant patients also to assist in the advancement of effective artificial pancreas therapy. Related StoriesInsulin dosage not independent risk element for cardiovascular deathOral formulation of insulin displays promise in general management of blood sugar in diabetic ratsVaccination against type 1 diabetes may shortly be available to youthful childrenThe two-calendar year grant, totaling $582,473, is supposed to fund study to build up Biodel’s proprietary ultra-rapid-performing insulin product applicant at high concentrations suitable for provide sufficient levels of insulin in an exterior artificial pancreas pump gadget which has a limited quantity capacity.